Skip to main content

Adaptive Biotechnologies: Leslie Trigg, Katey Owen, Eric Dobmeier, and David Goel

Adaptive Biotechnologies announced the appointments of Leslie Trigg and Katey Owen to its board of directors. Current board members Eric Dobmeier and David Goel, who both joined the board in September 2016, will retire.

Trigg is CEO of Outset Medical, a company that makes kidney dialysis technology. She has also held executive roles at Pro-Duct Health, FoxHollow, AccessClosure, and Lutonix. Trigg holds an MBA from the University of California, Berkeley Haas School of Business.

Owen is a director at the Bill & Melinda Gates Foundation with expertise in developing biologics and vaccines at Merck. Prior to joining the pharmaceutical industry, she was an influenza researcher at the UK's National Institute for Medical Research. She holds a doctorate in molecular virology from Purdue University.

Dobmeier is president and CEO of Chinook Therapeutics and Goel is cofounder and managing general partner of Matrix Capital Management.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.